subglutinol-a and Multiple-Sclerosis

Autoimmune diseases are chronic inflammatory diseases associated with high morbidity and mortality. Treatment options for autoimmune diseases have increased over the past several decades, but they are, in general, limited in their clinical efficacy due to high toxicity and lack of selectivity. Thus, efforts must be made to identify new immunomodulatory agents that are effective through a novel mechanism to circumvent existing side effects. To define the structural requirements of subglutinols for immunomodulatory activity and to provide guiding principles on future therapeutic development, we prepared and evaluated several subglutinol analogs for their immunomodulatory activities. Our efforts identified a subglutinol analog with reduced structural complexity as a potential lead compound for future autoimmune drug development. Our study will provide an important framework for the design of potent and nontoxic immunomodulating agents derived from subglutinols.

Topics: Animals; CD8-Positive T-Lymphocytes; Cell Survival; Diterpenes; Immunosuppressive Agents; Interferon-gamma; Interleukin-17; Mice, Inbred C57BL; Multiple Sclerosis; Pyrones; Th1 Cells; Th17 Cells